Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

What this study is about

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Who can join (things the study team will check)

✅ You may be able to join if…

• Participants with moderate-to-severe plaque psoriasis:
  • Deemed by the Investigator to be a candidate for phototherapy or systemic treatment for psoriasis, including ustekinumab;
  • Have at least 1 of the following cardiovascular risk factors:
• Current cigarette smoker
• Diagnosis of hypertension
• Diagnosis of hyperlipidemia
• Diabetes mellitus type 1 or 2
• History of one or more of the following cardiovascular events: Coronary intervention (PCI) or coronary artery bypass grafting (CABG), myocardial infarction (heart attack), cardiac arrest, hospitalization for unstable angina, acute coronary syndrome, stroke, or transient ischemic attack
• Obesity
• Family history of premature coronary heart disease or sudden death in a first-degree male relative younger than 55 years of age or in a first-degree female relative younger than 65 years of age.

🚫 You may not be able to join if…

• Participants must not have recent history of 1 of the following cardiovascular events: MI, stroke, or coronary revascularization, or VTE within 90 days prior to Day 1.
• Participants must not have unstable CVD, defined as a recent clinical cardiovascular event (eg, unstable angina, rapid atrial fibrillation), or a cardiac hospitalization (eg, pacemaker implantation, HF) within 90 days prior to Day 1.
• Participants must not have evidence of active cancer or history of cancer (solid organ or hematologic malignancy including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma, or carcinoma of cervix in situ that has been treated with no evidence of recurrence).
• Other protocol define inclusion/exclusion criteria apply.

Where this trial is running

• Local Institution - 0088, Birmingham, Alabama, United States
• Medical Dermatology Specialists - Phoenix, Phoenix, Arizona, United States
• Saguaro Dermatology - Phoenix, Phoenix, Arizona, United States
• Omni Dermatology, Phoenix, Arizona, United States
• Alliance Dermatology, Phoenix, Arizona, United States
• Local Institution - 0322, Scottsdale, Arizona, United States
• Local Institution - 0188, Scottsdale, Arizona, United States
• Scottsdale Clinical Trials, Scottsdale, Arizona, United States
• Omni Dermatology, Tempe, Arizona, United States
• Clinical Trials Institute of Northwest Arkansas, Fayetteville, Arkansas, United States
• Northwest Arkansas Clinical Trials Center (NWACTC), PLLC, Rogers, Arkansas, United States
• California Dermatology & Clinical Research Institute, Encinitas, California, United States

+ 379 more sites.

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07116967.